The Nature Accelerated Article Preview “SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801” was published online 09 FEB 2021. Co-first authors Angela Wahl and Lisa E. Gralinski used a human lung-only mouse model to show that therapeutic and prophylactic administration of EIDD-2801, an oral broad spectrum antiviral currently in phase II–III clinical trials, dramatically inhibited SARS-CoV-2 replication in vivo and thus has significant potential for the prevention and treatment of COVID-19. UNC core laboratories that contributed to this study include Animal Histopathology and Lab Medicine, Bioinformatics and Analytics Research Collaborative (BARC), High-Throughput Sequencing Facility, CFAR Biostatistics Core, and the Microscopy Services Laboratory.
Multiple Cores Contribute to SARS-CoV-2 Paper Published in Nature
